We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-10.00 | -2.23% | 437.50 | 430.00 | 445.00 | 447.50 | 437.50 | 447.50 | 27,309 | 15:06:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 47.02 | 209.75M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/7/2016 15:21 | Is this director share purchase enough to keep me interested in this boring performer I ask myself. | duncan doughnut | |
21/7/2016 14:49 | David Orr - the new boy and first time buy Re: his appointment. Is he being trained for the Chairmanship? | piedro | |
21/7/2016 14:38 | Directors buying shares as well now. | rcturner2 | |
21/7/2016 14:36 | From: Smartco Research {need to register} Research Standing This is a business which has adopted a very appealing low key approach to market entry vs. a big bang approach, but it is taking a long time to come to fruition - SMARTCO Research is continuing to follow the company because there was a change of chairman in June 2012 ... ... a meeting was held with him in March 2014, and SMARTCO Research can now understand why the commercial outlook for the company has significantly improved since he joined. The chairman referred to in the above para stepped down wef 15th October 2014, so it will be necessary to assess his successor as the company goes through a size barrier which requires experience on the board of successfully building a global business with a multisite operation. .... .... | piedro | |
21/7/2016 14:29 | Brummy, thank you for the link A sensible analysis by a more mature Equity team - AIMHO | piedro | |
21/7/2016 13:20 | Any feedback from the open day at all? | rcturner2 | |
21/7/2016 13:05 | Full note from Equity development www.equitydevelopmen | brummy_git | |
21/7/2016 10:42 | nice from FinnCapp too... "... The strong cash generation also resulted in a special dividend of 3p per share. Tristel is also debt free with a cash balance of £15.7mln. “The weakness in non-chlorine dioxide products did not fully materialise in H2 FY 2016 as we had expected, which together with continuing robust overseas growth, has led to upgrades to FY 2016 and 2017 forecasts,” said analysts at finnCap. The broker’s forecast for profit before tax increased from £0.2m and £0.3m to £3.1m and £3.5m in 2016 and 2017 respectively. finnCap raised its target price to 130p." | source | |
21/7/2016 10:27 | APAD I think the logic of the Aussie purchase is to enhance margins there. | bolador | |
21/7/2016 10:19 | Looks a sparkling update to me and a quick turnaround from all the doom and gloom of the previous update. Hell. even Piedro will have a good word to say! Lots to like today and the recovery is firmly on track. I would let the froth blow off today's rise before adding but I expect us to push on to 135 and 150p reasonably quickly. Well done to the Tristel board in this post-Brexit uncertain world. | mach100 | |
21/7/2016 10:01 | ps I know it's a small acquisition but the management responsibility os, perhaps significant and, perhaps difficult. | apad | |
21/7/2016 09:57 | Looking forward to feedback from the investor day. The presentation is not on the site yet. Don't understand the logic of buying the Oz distributor, ic2. Maybe the CEO or FD has relatives there? Maybe a more positive marketing presence. Dunno. The imminent 3p is a penance for past bad behaviour. More penances please. apad | apad | |
21/7/2016 09:50 | I think the only logical explanation is that there was a seller with an order to be worked through. | rcturner2 | |
21/7/2016 09:34 | Why did they suddenly drop down to 90p? | meijiman | |
21/7/2016 09:27 | Bought in here this morning after a rather positive trading update. I like the growth in sales particularly overseas which has increased to 41% in the second half of the year, from 36% in the first half. The acquisition of Australian distributor would seem to be earnings enhancing, and will look forward to an update at the full year results about progress in entering the US market. Also encouraged to see plenty of Director buying this year. TSTL are a very strong cash generator, hence the special dividend payments. | interceptor2 | |
21/7/2016 09:08 | By Equity Development:- "...In the US the process of seeking product authorisation from the FDA and EPA carries on at pace, and is on track to (hopefully) obtain approval in 12 months' time. We have duly upgraded our FY17 turnover and PBTA forecasts by +9% and +7%, to £19.5m and £3.54m respectively. Likewise, our fair value share price target climbs 8% to 135p." | source | |
21/7/2016 06:19 | Have some of that. Well done those who topped up at 90p recently. | rcturner2 | |
21/7/2016 06:18 | Super update! The Market couldn't ask for much more.. spud | spud | |
15/7/2016 07:40 | This is much better......has it been tipped somewhere??? | jaf111 | |
14/7/2016 14:00 | And from Goldshield Technologies ... [UK] Cleaner and Disinfectant with Residual Anti-Microbial Barrier - Unique non-leach molecular bonding technology - Long lasting continual protection (up to 7 days) - Minimises cross-contamination - Kills 99.999% of microbes - Alcohol free & non-corrosive | piedro | |
14/7/2016 13:42 | Should be a seller ...[USA] New wipe meets growing need for touchscreen compatible products in healthcare environments PDI's new Easy Screen cleaning wipe addresses the increasing use of touchscreen equipment in healthcare and the need for compatible cleaning products. | piedro | |
12/7/2016 16:55 | The number of shares traded does not look that significant, spud. Based on this I bought twice at 90p. I.e. no news, no change in story, just a low price? apad | apad |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions